Astrazeneca PLC Surges Ahead of the Stock Market in 2023, Closing at $67.26.
March 26, 2023
Trending News 🌥️
Astrazeneca ($LSE:AZN) PLC has been a star performer in the stock market this year, closing at $67.26 on the last trading day of 2023. This represents an increase of 1.04% from the previous day’s closing. The surge in the share price of this British-based pharmaceuticals giant reflects its growing presence in the global markets. The company, which is one of the largest pharmaceutical companies in the world, has continued to invest heavily in research and development (R&D). This has enabled it to bring innovative new medicines to market, which in turn has driven its share price higher. Astrazeneca PLC’s success in the market can also be attributed to its strong presence in emerging markets, with many of its products now being sold in countries such as China and India. Furthermore, Astrazeneca PLC has also seen an increase in its profits due to cost-cutting measures taken in recent years.
This has helped the company to remain competitive as well as providing a healthy return on investments for shareholders. The company has also benefited from the introduction of innovative new treatments, such as its cancer treatment, Tagrisso. As a result of these factors, Astrazeneca PLC’s share price has been climbing steadily throughout the year, far outperforming the overall stock market. With the company continuing to innovate and expand into new markets, this trend is expected to continue into the future. Investors who have invested in Astrazeneca PLC have been rewarded with a healthy return on their investment so far, and this is likely to continue.
Market Price
On Friday, ASTRAZENECA PLC stock opened at £110.1 and closed at £110.8, representing a 0.7% increase from its previous closing price of £110.0. The surge in prices appears to be related to strong performance in its core pharmaceuticals business, as well as a strong financial outlook for the future. Investors appear to be counting on AstraZeneca’s ability to deliver on its promises and generate sustainable growth in the long term. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Astrazeneca Plc. More…
| Total Revenues | Net Income | Net Margin |
| 44.35k | 3.29k | 8.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Astrazeneca Plc. More…
| Operations | Investing | Financing |
| 9.81k | -2.96k | -6.82k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Astrazeneca Plc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 96.48k | 59.42k | 23.9 |
Key Ratios Snapshot
Some of the financial key ratios for Astrazeneca Plc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 22.1% | 15.0% | 8.6% |
| FCF Margin | ROE | ROA |
| 16.3% | 6.6% | 2.5% |
Analysis
We at GoodWhale have performed an analysis of ASTRAZENECA PLC‘s fundamentals. Our Star Chart shows that ASTRAZENECA PLC is strong in dividend, growth, profitability and weak in asset. After further analysis, we classified ASTRAZENECA PLC as a ‘gorilla’ – a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. This makes ASTRAZENECA PLC an attractive proposition for investors looking for stability and long-term growth. In addition, its high health score of 7/10 considering its cashflows and debt indicates that the company is capable to pay off debt and fund future operations. This makes it an ideal prospect for those investors with a more risk-averse approach. More…
Peers
AstraZeneca PLC is a pharmaceutical company that specializes in the development, manufacture, and marketing of prescription drugs. The company has a diversified product portfolio, which includes medications for cardiovascular, gastrointestinal, and respiratory diseases, as well as cancer. AstraZeneca PLC competes with Sanofi SA, Merck & Co Inc, and Pfizer Inc in the global pharmaceutical market.
– Sanofi SA ($OTCPK:SNYNF)
As of 2022, Sanofi SA has a market cap of 100.1B and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and is one of the world’s largest pharmaceutical companies. Sanofi is a diversified company, focused on human health. It covers seven areas: diabetes solutions, rare diseases, multiple sclerosis, oncology, immunology, vaccines and consumer healthcare.
– Merck & Co Inc ($NYSE:MRK)
Merck & Co Inc is a pharmaceutical company with a market cap of 236.25B as of 2022. The company has a return on equity of 28.84%. The company produces a variety of drugs and vaccines for human and animal health.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a research-based pharmaceutical company with a market cap of 241.95B as of 2022. The company has a return on equity of 24.63%. Pfizer’s main focus is on the discovery, development, and commercialization of innovative therapeutics to treat patients with serious diseases. The company has a portfolio of products in various therapeutic areas, including cardiovascular, inflammation, immunology, oncology, pain, and rare diseases.
Summary
AstraZeneca PLC has been performing well in the stock market, closing at $67.26 in 2023. The media sentiment has been generally positive, indicating that investors are confident in the company’s performance and outlook. Analysts suggest that investors consider buying into AstraZeneca’s stock, as it offers attractive upside potential and has good fundamentals. The company’s revenue, earnings, and cash flow have been steadily increasing, and its dividend payout is among the highest in the industry.
It is highly rated by industry analysts and has strong financials and a diversified product portfolio. AstraZeneca also has an extensive research and development program that is likely to deliver new products to the market in the coming years. Investors should research the company thoroughly before investing.
Related Posts
Recent Posts
